PATENT CLAIM ANALYSIS

Application Number: 15942321
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-10
Patent Classification: ["514", "210020"]

Abstract:
Naphthyridine compounds and their use as inhibitors of HPK1 are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the naphthyridine compounds.

Claim (Index 33):
The compound of  claim 32 , wherein said bicyclic is wherein X\u2032 and Y\u2032 are each independently C, N, S, or O; and wherein said bicyclic is optionally substituted with R 17 , R 18 , R 19 , and R 20 , wherein R 17 , R 18 , R 19 , and R 20 , are each independently selected from the group consisting of hydrogen, hydroxyl, amino, and C 1-6  alkyl, and where two of R 17 , R 18 , R 19 , and R 20  taken together with the carbon to which they are attached can form a C 3 -C 5  spiro or C 2-9  heteroaryl ring.

Metadata:
- Claim Count in Document: 140.0
- Percentile: 90.0
- Lexical Diversity: 1.83333
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['12530648', '13102720', '15281923', '13266976', '15852639']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7848512637109736
- 35 USC 102 Novelty (BERT): 0.5130862237893297
- Combined Prediction Score: 0.7576747597188092
- Mean Citation Score: 269.39763800000003
- Max Citation Score: 276.27457000000004
- Similarity Product: 200.4572377501482

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test